Objectives: To present clinical experience with a regimen including abacavir/lamivudine + darunavir/ritonavir in a cohort of HIV-1-infected patients.
Introduction
Important advances in antiretroviral (ARV) therapy in the last decade have resulted in the prescription of effective and welltolerated regimens. However, in clinical practice, some limitations of ARV therapy persist and lead to discontinuation of therapy and the need for combinations that are not always recommended by international guidelines. 1, 2 Abacavir, lamivudine and darunavir/ ritonavir are ARV drugs commonly used in the routine care of HIV-infected patients. Based on the results of a number of clinical trials, they are recommended as a part of various treatment regimens. However, the combination of abacavir/lamivudine + darunavir/ritonavir has not been included in any guidelines and there is little published information on this regimen. 3, 4 Nonetheless, a number of patients are currently under treatment with this combination in clinical practice, at least in Spain. Here, we report our experience with abacavir/lamivudine +darunavir/ ritonavir in a cohort of ARV-naive and -experienced HIV-infected patients.
Methods
A retrospective, multicentre cohort study was conducted in 19 Spanish hospitals with extensive experience in HIV management. All consecutive adult HIV-1-infected patients who started abacavir/lamivudine + darunavir/ritonavir from April 2008 to December 2010 and had at least one follow-up visit were included. Data were collected between July 2012 and July 2013. Patients were ARV naive or ARV experienced without confirmed virological failure while receiving the previous ARV regimen [one detectable viral load (VL) related to poor adherence/toxicity at baseline, according to the investigator criteria, was allowed].
Clinical and laboratory assessments, including plasma HIV-1 RNA, CD4+ cell count and haematological and biochemical analyses, were performed at baseline, 1 month after starting treatment and every 3 -4 months thereafter, in accordance with routine clinical practice. Since 2008, HLA*B5701 is routinely determined in Spanish hospitals before an abacavir-containing regimen is initiated. However, HLA*B5701 determination was not an inclusion criterion because in HLA*B5701-positive patients abacavir is not initiated.
Patients received 600 mg of abacavir/300 mg of lamivudine (fixeddose combination) plus darunavir/ritonavir; in .90% of patients, darunavir/ ritonavir was given in a once-daily dose of 900/100 mg up to February 2010 and 800/100 mg thereafter. The primary outcome was the percentage of patients with HIV-1 RNA ,40 copies/mL after 48 weeks (+8 weeks) of therapy. The primary endpoint was analysed using the following approaches: on treatment (OT) analysis, intention to treat (ITT defining as failures patients who stopped ≥1 drug in the regimen regardless of the reason, and missing), ITT missing ¼ failure (ignoring treatment switches if VL undetectable at the switching) and ITT observed (excluding those with missing VLs). Virological failures were carried forward, which means that a patient discontinuing therapy due to virological failure was considered as a failure up to the end of follow-up.
Secondary outcomes were the percentage of patients with HIV-1 RNA ,40 copies/mL after 96 weeks (+8 weeks) of therapy, treatmentassociated toxicity, treatment discontinuations and reasons for discontinuation. Descriptive statistics were expressed as the median (range) for quantitative variables and as frequencies and percentages for qualitative variables.
A t-test for repeated measures was used for comparisons between follow-up and baseline results for continuous variables and Wilcoxon's signed-rank test was used when the variables did not display a normal distribution. To compare intragroup dichotomous categorical variables, the McNemar test was used. The Kaplan -Meier method was used to analyse the time to virological failure, failure or stop due to any reason. The study protocol was approved by the Hospital Ethics Committee of the co-ordinating centre.
Results
The baseline characteristics of the 183 patients studied (42 ARV naive and 141 ARV experienced) are summarized in Table 1 . In naive patients, 83.3% were men, the median age was 42.3 (21.4 -70.7) years, 19% were positive for hepatitis C virus (HCV) and 11.9% had prior AIDS. In experienced patients, 78.7% were men, the median age was 48.4 (25.4 -80.5) years, 44.7% were positive for HCV and 30.5% had prior AIDS. At baseline, the median CD4 count was 246 cells/mm 3 in naive patients and 393 cells/mm 3 in experienced patients and the median VL was 4.80 log copies/mL (63 447 copies/mL) and ,1.59 log copies/mL (,40 copies/mL), respectively. HLA*B5701 determination was available in 118 patients, and was negative in all of them.
Before the study regimen, all experienced patients had received nucleoside analogues, 89.4% protease inhibitors and 54.6% non-nucleoside reverse transcriptase inhibitors. The reasons for switching to abacavir/lamivudine + darunavir/ritonavir were toxicity in 54.6%, simplification to a once-daily regimen in 27.7% and others in 17.7% [non-specified medical decision (n¼ 8, 5.7%) and unknown (n¼ 17, 12%)].
The changes in VL both in naive and experienced patients are shown in Figure 1 . As expected, OT followed by ITT observed and ITT missing ¼ failure analyses were those with better results in both naive and experienced patients. Of 12 ARV-naive patients with baseline VL .100 000 copies/mL and receiving the regimen at 12 months, 7 (58.3%) reached undetectable VL. In experienced patients, those with undetectable VL at baseline (n ¼ 92) maintained higher percentages of viral suppression during follow-up, compared with the overall experienced population, as shown in Figure 1(c) .
Regarding CD4 count, in naive patients a gain of +176.5 (n ¼ 30) and +283.5 (n ¼ 22) cells/mm 3 was observed after 48 and 96 weeks (both P, 0.001), whereas in experienced patients the gain was +74.9 (n ¼ 110) and +93 (n ¼ 83), respectively (both P,0.001).
After a median follow-up of 26.7 (0.5 -58.6) months, the regimen was discontinued in 47% (n¼86) of patients, but the reason was probably unrelated to medical criteria in a proportion of them. The main cause was regimen simplification to reduce drug cost (28 patients: 20 monotherapy with darunavir/ritonavir, 4 tenofovir/ emtricitabine/efavirenz and 4 abacavir/lamivudine/nevirapine) and 11.5% (n ¼ 21) were lost to follow-up (a number of patients changed their address due to economic constraints). Three patients died due to reasons unrelated to the study drugs and 19 (10.4%) discontinued one or more of the study drugs due to adverse events. Of these, nine patients had dyslipidaemia, three had gastrointestinal symptoms, two had suspected hypersensitivity due to abacavir and the following conditions occurred in one patient each: renal failure, neutropenia, arthralgia, lipodystrophy and osteoporosis. Finally, other causes were reported in nine (4.9%) patients (acute hepatitis C or chronic hepatitis C or hepatitis B treatment in six cases, enrolled in a clinical trial in one case and reason not reported in two cases). The time to virological failure or failure or stop due to any reason was assessed by Kaplan -Meier analysis; a median of 39.3 months was obtained (95% CI 30.6-48.0 weeks) and the percentage of patients with event was 47.5% (n¼ 87).
After 48 weeks, a significant change in lipid parameters from baseline was observed in naive patients: +0.69 (range 22.28; 
Discussion
This is the largest reported cohort of patients treated with a regimen of abacavir/lamivudine +darunavir/ritonavir. Our data suggest that this combination may be effective and well tolerated in ARV-naive and -experienced HIV-infected patients, in accordance with the findings obtained in smaller patient series. 3 -5 In clinical trials, patients are voluntarily recruited and the efforts of both physicians and patients enable continuation of treatments despite minor or moderate toxicities or non-medical reasons. In routine clinical practice, however, a number of factors can ultimately lead to a change of treatment. In recent years, the economic crisis has favoured a trend to use less-expensive ARV drugs without clear medical reasons in a considerable percentage of patients. Furthermore, many immigrants have returned to their countries of origin because of economic constraints and also Spanish people have moved to other regions trying to find a job. In the present study, although we do not know the exact number, we speculate that a proportion of patients discontinuing the study regimen did so related to these circumstances. Only 10% of the Abacavir/lamivudine + darunavir/ritonavir in clinical practice 2539 JAC total discontinued because of toxicity, a value that is not higher and even lower than some reported rates for other regimens used in routine clinical practice. In patients continuing with the regimen, the virological and immunological responses were clearly favourable. In both naive and experienced patients, .80% had undetectable VL after 48 weeks of therapy and .90% after 96 weeks. Our data suggesting a lower virological response in naive patients with high baseline VL coincide with the findings of Nishijima et al., 4 although both series are limited in number. In addition, a good CD4 response was observed in both HIV populations, with a higher increase in naive patients, as would be expected.
It is well recognized that the use of ritonavir-boosted protease inhibitors is associated with an increase in lipid levels in a number of patients, as well as an increase in cardiovascular risk. 6 Although darunavir/ritonavir and atazanavir/ritonavir seem to promote a more favourable lipid profile compared with older compounds and lopinavir/ritonavir or fosamprenavir/ritonavir, 7 hyperlipidaemia was the main reason for discontinuation due to toxicity. A significant increase in lipid levels (including a favourable HDL increase) was observed in naive patients, as usually occurs in association with the decrease in VL. However, this was not the case in experienced patients, most of who had switched from other PI-boosted regimens. As occurs with other regimens leading to an increase in lipid levels, this regimen should be used with caution in patients at cardiovascular risk. However, it remains a controversial issue because some studies have suggested an association between abacavir and increased cardiovascular risk, whereas others have not confirmed these findings, 8, 9 international guidelines continue to call for care with the use of this drug in patients with a high risk of cardiovascular disease.
Our study has several limitations due to its retrospective noncomparative design and the relatively small sample size, mainly regarding naive patients. However, as was mentioned above, it is the largest experience to date with the use of this regimen. Thus, although our results should be considered with caution and a randomized clinical trial would be advisable, the data may be useful for clinicians who need to use these drugs in combination in routine clinical practice.
In summary, abacavir/lamivudine + darunavir/ritonavir may be an effective and well-tolerated alternative regimen for naive and experienced HIV-1-infected patients. In our current clinical practice, non-medical reasons seem to have led to a change of this effective regimen in a proportion of patients.
